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Abstract
Background: Multimodal analgesia is achieved by combining different analgesics and different methods of analgesic
administration, synergistically providing superior pain relief when compared with conventional analgesia. Multimodal
analgesia can also result in reductions in the side effects and complications of analgesia, thereby improving patient
safety. Preventive analgesia, treatment before initiation of the surgical procedure, has a potential to be more effective
in reducing pain sensitization than treatment initiated after surgery. Multimodal analgesia that includes prophylactic
administration of selective cyclooxygenase-2 (COX-2) inhibitors can improve postoperative pain and reduce opioid
analgesic consumption after total knee arthroplasty (TKA). However COX-2 inhibitors are not approved for use as
preventive analgesia in Japan. Thus, assessing the effectiveness of COX-2 inhibitors during the early postoperative
period is important to establish clinical practice guidelines in Japan. This study was designed to examine the effects of
celecoxib administration immediately after surgery, in addition to multimodal analgesia, on postoperative pain
management after TKA.
Methods/Design: This randomized, prospective, open-label controlled study will include 120 patients undergoing
unilateral TKA. All patients will routinely receive single injections of femoral and sciatic nerve blocks, along with
postoperative patient-controlled analgesia (PCA) with fentanyl. Patients will be randomly assigned to receive or not
receive immediate postoperative administration of celecoxib. The primary outcome is a visual analog scale (VAS) pain
score the second day after surgery. Secondary outcomes include opioid consumption, VAS pain score for 7 days after
surgery, range of knee motion, evaluation of sleep quality, overall evaluations by patients and physicians, rates of
postoperative nausea and vomiting, and consumption of rescue analgesics.
Discussion: The objective of this study is to evaluate the effects of celecoxib administration immediately after surgery
on pain after TKA surgery. A randomized controlled trial design will address the hypothesis that administration of oral
celecoxib immediately after surgery, along with multimodal analgesia that includes peripheral nerve block and PCA,
could reduce VAS pain score after TKA surgery.
Trial Registration: UMIN-CTR 000014624 (23 July 2014)
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Background
Surgical procedure could cause noxious stimulation. Many
methods have been used to manage pain after surgery, in-
cluding various drugs, routes of drug administration and
medication methods. Recently, patient-controlled analgesia
(PCA) has been more widely used because of its thera-
peutic effects and safety [1]. PCA is a method of allowing a
patient with pain to administer his own pain relief. The in-
fusion is controlled by electronically pump, that delivers
prescribed amount of analgesic when a patient press a but-
ton. Preventing a patient from overdosing analgesics, a
dosage and interval of analgesics are programmed. Patients
can self-administer drugs whenever they need analgesics,
regardless of broad inter-individual differences in demands
for analgesia, thus minimizing inter-individual differences
in pharmacokinetics and pharmacodynamics.
Multimodal analgesia is achieved by combining differ-
ent analgesics and different methods of administration,
to provide superior pain relief synergistically compared
with conventional analgesia [1]. Moreover, rates of side
effects and complications of analgesics are reduced with
multimodal analgesia, improving patient safety. The up-
dated 2012 American Society of Anesthesiologists prac-
tice guidelines for acute pain management during the
perioperative period recommend multimodal techniques
for perioperative pain management [1].
Surgical noxious stimuli sensitize the nervous system
to subsequent stimuli that could amplify pain. Preventive
blocking of nociceptive stimuli to the central nervous
system is beneficial in attenuating postoperative pain and
in reducing the severity of postoperative pain [2]. Prevent-
ive analgesia is a concept for reducing this sensitization
before the surgical procedure initiates [2]. Preventive
analgesia could be more effective than a similar analgesic
treatment initiated after surgery. Surgical trauma induces
cyclooxygenase (COX) expression and subsequent syn-
thesis of prostaglandins (PGs), which sensitize periph-
eral nociceptors and cause nociceptive pain. Since non-
steroidal anti-inflammatory drugs (NSAIDs) can inhibit
COX and inhibit the synthesis of PGs, NSAIDs are widely
used to reduce postoperative hyperalgesia [3].
Traditional NSAIDs inhibit both COX-1 and COX-2
isoenzymes. Celecoxib is a selective COX-2 inhibitor
shown to be as effective as traditional NSAIDs as an an-
algesic for acute postoperative pain. Celecoxib has fewer
gastrointestinal side effects than traditional NSAIDs,
such as loxoprofen, diclofenac and ibuprofen [4–6]. More-
over, celecoxib has no effects on serum thromboxane and
platelet functions, suggesting that it may be an effective
postoperative analgesic [7].
Studies have suggested that the administration of select-
ive COX-2 inhibitors for preemptive, multimodal analgesia
can improve postoperative pain and reduce the con-
sumption of opioid analgesics after total knee arthroplasty
(TKA) [8, 9]. In Japan, however, celecoxib, as well as other
NSAIDs, has not been approved for use as preemptive
analgesia, but only for postoperative analgesia. Assessing
the effectiveness of COX-2 inhibitors as a constituent of
multimodal analgesia during the early postoperative period
is important to establish clinical practice guidelines.
This study was designed to assess the effects of cele-
coxib administration during the early postoperative period,
along with multimodal analgesia, on postoperative pain
management after TKA. We hypothesized that the admin-
istration of celecoxib immediately after TKA surgery would
provide superior postoperative analgesia compared with
delayed administration. Our aim is to compare patient-
reported visual analog scale (VAS) pain scores, opioid con-
sumption, range of knee motion, sleep quality, rates of
postoperative nausea and vomiting, and rescue analgesic
consumption in patients who do and do not receive
COX-2 inhibitors, as well as to compare overall evalua-
tions by patients and physicians.
Methods/Design
Study design
This study is a single-center, randomized, prospective,
open-label controlled trial, performed in accordance with
the Declaration of Helsinki and approved by the ethics
committee of the Tsukuba University Hospital Mito Clin-
ical Education and Training Center, Mito Kyodo General
Hospital, University of Tsukuba. Written informed consent
will be obtained from each patient prior to enrollment
and testing. This study follows the CONSORT statement
(http://www.consort-statement.org/). The trial is registered
under the University hospital Medical Information Net-
work and clinical trial registry (UMIN-CTR; http://
www.umin.ac.jp/ctr/index.htm) 000014624 (23 July 2014).
An overview of the trial design is shown in Figs. 1 and 2.
Eligibility and recruitment
Patients undergoing unilateral TKA as a result of osteo-
arthritis or rheumatoid arthritis will be recruited from the
Department of Orthopaedic Surgery and Sports Medicine,
Tsukuba University Hospital Mito Clinical Education and
Training Center, Mito Kyodo General Hospital, University
of Tsukuba. Identified patients will be approached for in-
clusion into the study based on the inclusion/exclusion
criteria described below.
Enrollment criteria
Inclusion criteria
Patients will be eligible for inclusion if they are aged ≥
20 years, undergoing unilateral TKA in the morning as a
result of osteoarthritis or rheumatoid arthritis, can under-
stand and comply with the study protocol, have signed
the informed consent document at screening, and
have been assessed by the principal investigator and/or
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co-investigator as eligible for pain control with multi-
modal analgesia (including femoral and sciatic nerve
blocks and PCA fentanyl after TKA surgery).
Exclusion criteria
Patients with a history of complications or hypersensitiv-
ity to celecoxib, fentanyl or sulfonamides; a serious aller-
gic reaction to any other drugs; aspirin-induced asthma;
or gastrointestinal hemorrhage or ulcer will be excluded.
In addition, patients will be excluded if they have severe
hepatic, renal, or cardiovascular dysfunction; are in a
perioperative period of coronary artery bypass surgery;
are pregnant, lactating or probably pregnant. Patients
with a history of drug abuse will be excluded. In this
study, sleep quality will be evaluated. Hypnotic drugs
could alter the sleep state. The central nervous system
active medicines often alter the occurrence, latency of
specific sleep and dream state, with either therapeutic
intent or side effects [10]. In addition, benzodiazepines
are rapid eye movement (REM) sleep-suppressant medi-
cations, and could induce a withdrawal syndrome with
REM rebound [10]. Therefore, those who take or will
take a hypnotic drug from 2 days before surgery to final
evaluation will be excluded, although ultrashort-acting
hypnotic drugs, including triazolam, zopiclone and zolpi-
dem tartrate, are permitted until surgery.
Randomization
The objective of this study is to evaluate the effects of
additional postoperative celecoxib administration on pain
after TKA surgery. All patients will routinely receive a com-
bination of femoral/sciatic nerve blocks and postoperative
Fig. 1 Enrollment: flow diagram of the trial design. Abbreviations: TKA, total knee arthroplasty; OA, osteoarthritis; RA, rheumatoid arthritis; PCA,
patient-controlled analgesia
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fentanyl PCA and be randomized using a computer-
generated list to one of two groups, one of which will
receive immediate postoperative celecoxib (celecoxib group),
whereas the other will not (control group).
A computer-generated scheme will randomize patients
in a 1:1 ratio matched by illness, either osteoarthritis or
rheumatoid arthritis. Patients will be assigned to either
intervention or control group within 14 days before
surgery. Randomization will be performed centrally by
Tsukuba Critical Path Research and Education Integrated
Leading Center (CREIL center), Tsukuba Critical Path Re-
search and Education Integrated Leading Center (CREIL
center) Tsukuba Clinical Research and Development
Organization (T-CReDO), University of Tsukuba.
Intervention plan
Dosage, route of administration, and period of
investigational drugs
In accordance with the package insert, and as in a previ-
ous study [9], the first oral dose of celecoxib will be
400 mg, followed by 200 mg in both the celecoxib and
control groups. Patients in the celecoxib group will receive
400 mg celecoxib 2 hours after TKA, followed 6 hours
later by 200 mg celecoxib and 200 mg celecoxib twice
daily beginning the day after surgery until day 7. Patients
in the control group will receive 400 mg celecoxib on the
morning of the second day after surgery, which is the
day of PCA fentanyl removal, followed 6 hours later by
200 mg celecoxib and 200 mg twice daily until the seventh
day after surgery [9].
Perioperative analgesia
Surgery will be performed under general anesthesia. After
general anesthesia is induced, a single injection of per-
ipheral nerve blocks, consisting of 25 ml of 0.375 %
ropivacaine hydrochloride as a femoral nerve block and
25 ml of 0.2 % ropivacaine hydrochloride as a sciatic nerve
block, will be administered under ultrasound guidance.
Postoperative analgesia will consist of PCA with fen-
tanyl citrate. At the end of surgery, the PCA pump will
be started at a basal rate of 10 μg per hour. An on-demand
mode will be programmed, allowing for bolus injections of
15 to 20 μg every 5 minutes, with the maximum basal and
bolus doses allowed per hour being 250 μg.
Rescue analgesic
Patients who require an additional analgesic after PCA
fentanyl removal on the second day after surgery will be
allowed a 25 or 50 mg diclofenac sodium suppository.
Usage of the rescue analgesic will be recorded.
Outcomes
Primary outcome measure
The primary outcome measure in this study will be patient-
reported VAS pain score at 9 o’clock on the second day
after TKA. This measure will allows us to identify the effect
of early administration of celecoxib (Table 1).
Secondary outcome measures
For secondary outcome measures, fentanyl consumption
through PCA is assessed at 2 days after surgery; VAS
Fig. 2 Allocation: flow diagram of the intervention. Abbreviations: TKA, total knee arthroplasty; PCA, patient-controlled analgesia
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pain score is assessed at 9 a.m. each day from 1 to 7 days
after surgery; range of motion of the knee joint is assessed
at 9 a.m. at 2 and 7 days after surgery; postoperative sleep
quality is evaluated at 1, 2 and 7 days; overall patient satis-
faction during the period of medication is evaluated at
7 days after surgery; overall evaluation by the physician
during the period of medication is assessed at 7 days
after surgery; incidence rates of postoperative nausea
and vomiting and frequency of taking anti-nausea pills
is assessed for the 7 days after surgery; and consumption
of rescue analgesics (diclofenac sodium suppositories)
after the discontinuation of PCA fentanyl is assessed over-
all for the 7 days after surgery (Table 1).
Sleep quality at 9 a.m. on postoperative 1, 2 and 7 days
will be evaluated by patient-reported VAS sleep dis-
turbance. For objective sleep assessment, sleep latency,
sleep efficacy, nocturnal awakening, depth of sleep,
body motion, and deep sleep time will be monitored
by SLEEPSCAN™ (TANITA Corporation, Japan) [11].
SLEEPSCAN monitors body motion, breathing, and
heart rate through the bedding mattress with a water
seal and pressure sensor, without the necessity of in-
stalling direct sensors, including bioelectrodes, on the
human body [11].
Assessment of safety
Administration of study drugs will be immediately stopped
in participants who show relevant deterioration. Severe ad-
verse events, as determined by the Common Terminology
Criteria for Adverse Events (CTC-AE) ver. 4.0, will be re-
ported to the principal investigator, who will report any
unexpected serious adverse reactions to the institution.
Data collection
Data collection across time points is shown in Table 1.
Data collection is performed by research assistants for
VAS pain score, fentanyl consumption, VAS sleep score,
SLEEPSCAN, patient satisfaction, PONV, and rescue con-
sumption. Physical therapists will measure knee ROM. Re-
search assistants and physical therapists are independent
of the clinical management of the subjects. The collected
data will be transferred to the T-CReDO data center as
soon as each patient completes the schedules, and will
be analyzed by an independent researcher. After col-
lecting data, an independent clinical research coordin-
ator will verify the data collection by confirming medical
records. These processes will be unaffected by any
researchers.
The validation of collected data for this cohort is im-
portant. Previously, patient-reported VAS pain score has
been well validated [12–14]. Because of its practicality,
reproducibility, sensitivity to treatment effects, and ease
of analysis, the VAS pain scale is a powerful research
tool in the field of pain research. No significant differences
have been observed in VAS pain score for each of the
variables including age, sex, and cause of pain [14]. In
addition, patients’ satisfaction and sleep quality are also
validated previously [11, 15]. Therefore, the collecting
data from this study is believed to be validated.
Sample size calculation
The primary outcome of this study is patient-reported
VAS pain score on the second day after surgery, based
on the hypothesis that immediate postoperative adminis-
tration of oral celecoxib could reduce patient-reported
VAS pain score 48 hours after TKA surgery compared
with the control group.
Sample sizes are chosen to detect clinically relevant
differences using a power analysis based on previously
published data evaluating the effect of celecoxib on VAS
pain score after TKA [9]. The minimal clinical significance
in VAS pain score was defined as the mean difference
Table 1 Data collection schedule
Day before surgery Day of surgery Postoperative day(s) Discontinuance
1 2 3–6 7
VAS pain score ● ●a ●b ●b ●b ●b ●
Fentanyl consumption ● ● ●
ROM ● ● ● ●
VAS sleep scorec ● ● ● ● ● ●
SLEEPSCAN™ % ● ● ● ● ● ●
Patient satisfaction ● ●
Evaluation by physician ● ●
PONV ● ● ● ● ● ●
Rescue consumption ● ● ● ●
Adverse events ● ● ● ● ● ●
aTwo hours after the end of surgery; b9 a.m. before oral administration; cevaluation the next day; % overnight measurement
Abbreviations: VAS visual analog scale; ROM range of motion of the knee; PONV postoperative nausea and vomiting
SLEEPSCAN™ (TANITA Corporation, Japan) is a tool for evaluating sleep quality
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between current and preceding scores when the subject
reported “a little worse” or “a little better” pain [12].
Previous study shows that VAS pain scores 48 hours
after TKA surgery were reported to be 21.3 ± 16.8 mm
in patients receiving celecoxib plus PCA morphine and
34.3 ± 16.6 mm in patients receiving PCA morphine
alone [9]. Based on these findings, we hypothesized that
VAS pain score 48 hours after surgery will be 22 mm
for the celecoxib group (postoperative oral celecoxib
plus nerve block and PCA fentanyl) and 33 mm for the
control group (nerve block and PCA fentanyl alone),
with a standard deviation set at 20.0 mm and a ratio of
patients in the celecoxib to the control group of 1:1.
Calculations showed that a sample size of 53 patients
per group would provide 80 % power (alpha = 0.05, two-
tail) to detect a difference in VAS pain score between the
two groups after treatment, and also the minimal detect-
able change of 10 mm within each group [9]. Assuming a
10 % dropout rate, 60 patients per group, or a total of 120
patients, are required.
Plan for statistical analysis
The intention-to-treat analysis will be conducted for all
patients who underwent randomization. Baseline infor-
mation on study subjects in two treatment groups such
as demographics, preoperative VAS pain scores, ranged
of motion and sleep quality will be described. The pri-
mary outcome that the differences of VAS pain scores
between celecoxib and control groups at the second day
after surgery will be analyzed by ANOVA. The second-
ary outcomes including the pain-medication use, adverse
reactions, VAS pain scores, range of motion of knee joint,
sleep quality, patient satisfaction, and overall evaluation by
physicians after surgery will be analyzed by ANOVA or
Chi square test. Nonparametric tests may be used for
continuous variables if they are not normally distributed.
Between-group comparisons of treatment effect for primary
and secondary outcomes, except for pain-medication use
and adverse events, will also be conducted with the use of a
mixed-effects model, with patient as a random effect and
time of assessment (baseline and follow-up days), study
group, and baseline values of the outcome as fixed effects.
Significance will be set as P < 0.05. All statistical ana-
lyses will be performed by using SAS 9.4 (SAS Institute
Inc., Cary, NC, USA).
Discussion
To achieve less postoperative pain, better patient satisfac-
tion, and better rehabilitation after surgery, pain manage-
ment is very important. Multimodal analgesia for pain
management after surgery has been shown effective in
controlling postoperative pain [1]. Previously, prophylactic
administration of a COX-2 inhibitor, as a multimodal an-
algesia, has been found to reduce postoperative VAS pain
score, opioid analgesic consumption, and active ROM of
the knee after TKA surgery [8, 9]. In these studies, a
COX-2 inhibitor is administered before surgery.
COX-2 inhibitors and other NSAIDs have only been
approved as postoperative, but not as preemptive, anal-
gesia in Japan. In addition, an appropriate fasting period
to empty the stomach prior to anesthesia is essential for
patient safety, because the risk of inhaling stomach con-
tents into the lungs is reduced. Thus, to verify the effect-
iveness of administration of a COX-2 inhibitor during the
early postoperative period as part of multimodal analgesia,
it is necessary to establish clinical practice guidelines. In
addition, this method of administration is safe, convenient
and general-purpose way in practice. To date, however, no
comparative data are available.
This randomized controlled trial design will be used
to address the hypothesis, that immediate administra-
tion of oral celecoxib after TKA surgery provides su-
perior postoperative analgesia when compared with
delayed administration.
The primary outcome of this study is to evaluate the
effects of celecoxib administration immediately after sur-
gery on postoperative pain after TKA. Possible benefits
of celecoxib include its ease of administration, safety after
surgery, its effectiveness and reduction of postoperative
opioid consumption. Thus, this study might to identify
the influence of immediate administration of oral cele-
coxib after TKA surgery. This will help to provide clinical
management status for patients with TKA surgery.
Opioid consumption for the secondary outcomes will
be determined. Opioid is useful and effective for postsur-
gical pain control. However, the incidence rates of post-
operative nausea and vomiting as its side effects could
be increased with large amounts of opioid. By taking
medicine for pain relief after the early post-operative
period, opioid consumption and its side effects could be
reduced. As its other expectations, pain relief after sur-
gery might improve the quality of sleep. When postoper-
ative pain is reduced, the range of knee motion with
accelerated physical recovery might be improved. Pain
relief, good quality of sleep and early functional recovery
could improve satisfaction of patients. These will be very
important to establish clinical practice guidelines.
The limitation of this study is an open label. However
our data will come from patient-reported outcomes and
participants will not be affected by any other. Patient–re-
ported outcome will help to understand practical patients’
condition. Therefore, we believe that this study will pro-
vide some insight into perioperative multimodal analgesia,
which helps to improve perioperative clinical practice.
Clinical relevance and importance
This randomized controlled trial will help to provide
insight to optimize perioperative pain management
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strategies by evaluating the effect of immediately post-
operative administration of analgesics for patient after
TKA surgery. These results could improve clinical practice
for perioperative pain management and also might help
to improve patient satisfaction.
Trial status
Patient recruitment started in October 2014. The predicted
study completion date is March 2016.
Abbreviations
COX: cyclooxygenase; NSAIDS: nonsteroidal anti-inflammatory drugs;
OA: osteoarthritis; PCA: patient-controlled analgesia; RA: rheumatoid arthritis;
TKA: total knee arthroplasty; VAS: visual analog scale.
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